The court’s latest move, which allows the companies to use Roche’s product data in their package inserts, is expected to allow Biocon and M...

Biosimilars are copies of complex drugs based on living cells. They are different from chemical-based generic drugs, which are 'identical' ...

Legal experts said that the court is still in the process of hearing arguments from both sides to ascertain whether Roche could have approa...

Roche sued Zydus Cadila and the DCGI last week, alleging that the Indian company launched its product, Vivitra, in the country without gene...

The petition states the approval of Cadila’s drug as a biosimilar has caused Roche “irreparable damage” in violation of applicable law for ...

Roche did not comment on the development, stating that the matter was sub judice. Biocon did not respond to ET's queries.

The ministry expects the final guidelines to uphold the safety and efficacy of biosimilar drugs hitting the Indian market through stringent...

The counsel is appealing conditions including the restrictions placed on the labelling of TrastuRel as well as those placed on using Roche’...

On May 9, the NPPA issued a notification capping the price of trastuzumab 440mg/50ml injections at Rs 55,812.29 per pack.

The order, which raised questions on the processes followed by the Indian drug controller in approving such drugs, could also affect the av...

Zydus Cadila has introduced a breast cancer drug in India that is a copy of Swiss giant Roche’s product Herceptin, which had global sales o...

Roche Products (India) Private Ltd is a wholly owned subsidiary of the Switzerland based Roche Group and has products in therapeutic areas .

India is a fragmented market and has its own challenges; there is a private sector and public sector. About 80% of the healthcare expenses ...

Roche said patients will be offered equated monthly instalment schemes for Perjeta and Kadcyla through financial institutions in the coming...

Bangalore-based Biocon and US generic drugmaker Mylan have challenged Delhi High Court’s interim order which barred them from using Roche’s...

Biocon officials confirmed the development to ET but didn't shed light on how soon the company would be ready to bring the biosimilar to th...

Worried over the exorbitant prices of the drug in the Indian market, the ministry urged the DIPP to invoke this section.